TERNS PHARMACEUTICALS INC (TERN)
US8808811074 - Common Stock
Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
FOSTER CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...
TERN Crosses Above Key Moving Average Level
Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia
Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia
Compelling molecular responses starting at lowest dose level in heavily pre-treated patients with high baseline BCR-ABL transcript levels Encouraging...
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...
Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
Accomplished biotechnology CEO brings 25 years of strategic, operational, and legal experience
Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
Accomplished biotechnology CEO brings 25 years of strategic, operational, and legal experience...
Terns Pharmaceuticals is Now Oversold (TERN)
Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates
Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
Notable Two Hundred Day Moving Average Cross - TERN
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
Terns has a modest market cap of less than $800 million, and its possible upside could be massive.
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
Terns Pharmaceuticals just proved that it's competitive in the weight loss field.
Should You Invest in This Under-the-Radar Weight Loss Stock?
Getting in on the ground floor sounds like a great idea, but not if the building ends up crumbling.
1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More
This biotech's data suggests that it could have an advantage in its target market.
Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
FOSTER CITY, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...
Terns Announces Pricing of Upsized $150.15 Million Public Offering
Terns Announces Pricing of Upsized $150.15 Million Public Offering
FOSTER CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...
First Week of September 20th Options Trading For Terns Pharmaceuticals (TERN)
Terns Announces Proposed Public Offering
Terns Announces Proposed Public Offering
FOSTER CITY, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...
Noteworthy Monday Option Activity: TERN, HLF, ACI
Monday Sector Leaders: Biotechnology, Drugs
Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo adjusted) Well-tolerated with no treatment-related dose interruptions,...